Atsushi Fujio

Division of Transplantation, Reconstruction, and Endoscopic Surgery, Tohoku University Hospital.

Biography

ABO-incompatible living donor liver transplantation (ABOi-LDLT) is essential for expanding the donor pool. ABOi-LDLT prognosis has improved since desensitization treatment with rituximab; however, patients with high antibody titers are considered to be at high risk of antibody mediated rejection (AMR).